These earnings winners are red hot 🔥 (2024)

*Together with

💊See Today’s Top Biotech Stock Idea!💊

Good day, 360 –

Here are our top 3 trade ideas today...plus a BOATLOAD 🛥️ of top headlines today. Be the best prepared trader on the Street!

ASAN - 18% higher after better than expected earnings

ARLO - 2nd day play, closes up over 50% after earnings beat

NLTX - Over 30% higher after announcing review of strategic alternatives, corporate restructuring and layoffs

*A message from Market Research Repository

🔥 Hot Stock of the Day 🔥

We don’t get an opportunity like this too often.

Today, we are introducing a $1 stock that has enormous potential.

The company is sitting on a mountain of cash right now ⛰️💰

The founders have personally invested over $26 million dollars to date, but the company also reports around $10 million of cash on hand on top of this.

The company has not 1 or 2 upcoming catalyst events – but FIVE upcoming “shots on goal” for investors to look forward to (several coming soon!).

This is a very unique opportunity, and we think you will love getting to learn more about this company.

Click here to learn more about this exciting stock right now!

*Sponsored by Lifewater Media, see disclosures below

ASAN - 18% higher after better than expected earnings

ASANA (ASAN) reported Q4 EPS of -$0.15 vs -$.27 expected. Revenue for the quarter came in at $150.2 million versus $145.08 million consensus. Perhaps more importantly ASAN provided guidance for full year 2024 EPS of -$0.59 to -$0.55 versus the -$0.80 consensus. The CEO also entered into a trading plan to buy up to 30 million shares showing confidence in the company and investors responded positively to the news.

The $21.20 area was support in the pre-market and should be an important pivot level.

Above it, targets to the upside are $22, $23.30 and then the after-hours high of $24.36 with $26 above that.

Below $21.20, there is potential support at $19.25 and then a gap fill to $17.80.

ARLO - 2nd day play, closes up over 50% after earnings beat

Arlo Technologies (ARLO) closed yesterday near the highs of the day, up over 50%. They reported earnings of -$0.04 vs -$0.10 estimate with sales of $118.50 million vs $107.44million estimate. They also guided full year 2023 adjusted EPS between -$0.07 to -$0.01 vs -$0.12 estimated which was the catalyst for the move higher yesterday.

$5.40 was a resistance area yesterday and should be an important pivot level.

Above it, targets to the upside are $5.53 with $5.91, $6 and $6.50 above that. Further targets are at $6.74 and $7.30.

Below $5.40, there is potential support at the $5-$5.08 area with potential support at $4.90, $4.65, $4.30, and then $4.15 below that.

NLTX - Over 30% higher after announcing review of strategic alternatives, corporate restructuring and layoffs

Neoleukin Therapeutics (NLTX) provided a strategic update late Wednesday announcing they had engaged SVB Securities to assist in reviewing strategic alternatives for the company with the goal of maximizing shareholder value.

They also announced a reduction in the company’s workforce by 70% and a leadership transition.

The market has responded positively and the stock is trading over 30% higher in the pre-market.

$0.6850-$0.7000 has acted as an area of support so far in the pre-market.

Above it, $0.73-$0.75 has so far acted as resistance with the after-hours high at $0.78. Above that potential targets are $0.90, $0.95 and then $1.

Below $0.6850 there is potential support at $0.6350, with targets of $0.60, $0.56 and then a gap to fill at $0.5302 below that.

Economic Calendar (EST)

7:30am Challenger job cuts

8:30am Jobless claims

10:00am Fed Speaker Michael Barr

10:30am EIA Nat gas report

Earnings for Today (After Market)

ACHR, AEYE, AGIL, AGS, AIRG, AKA, ALGS, ALTG, ALTO, AMPY, AOUT, APPH, AQMS, ATER, AVO, AVPT, AWRE, BBCP, BIRD, BKKT, BNGO, BWMN, CLSD, CMTL, CRIS, CTSO, DALN, DOCU, DOUG, GEVO, GHLD, GPS, GRTS, HCI, HCP, HGBL, HRT, HYFM, III, INUV, IRIX, JAKK, JSDA, JYNT, LCTX, LIFE, LMNR, LOCO, LRFC, LTM, MTN, MYPS, NNBR, NX, ODC, ONCT, ORCL, PAM, PTMN, QFIN, RAIN, REI, RGLS, SBIG, SMSI, STKS, TGS, TLYS, TOI, ULTA, VEL, WATT, WLDN, YPF, ZUMZ

Top Headlines

SI: Silvergate Capital Corporation Announces Intent to Wind Down Operations and Voluntarily Liquidate Silvergate Bank

NLTX: Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

DRTS: Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

LLY: Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

SWTX: SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

MGNX MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

UUUU: Energy Fuels Announces 2022 Results; Emerging as the Leading US Producer of Critical Minerals with Focus on Uranium and Rare Earth Elements

U.S. FDA-working to address shortage of particular form of albuterol-medication that is used to treat breathing conditions

QGEN: QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

MASI: New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery

AFMD: AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery

BPTS: Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

SPI: SPI’s Solar4America Showing American-Made 550W C&I Solar Modules at Solar + Wind Finance & Investment Summit 2023

BJ: Total comparable club sales increased by 9.8% year-over-year

Comparable club sales, excluding gasoline sales, increased by 8.7% year-over-year

GENI: NBA and Genius Sports / Second Spectrum Expand Partnership to Deepen NBA League Pass Innovations with Enhanced Basketball Analytics and Develop New Next Gen Platform

PFE: Pfizer ready to launch its rsv vaccine this year in U.S. and EU, pending approval, for both older adults and pregnant women-executives

CLNN: CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

NYMT: New York Mortgage Trust Completes One-for-four Reverse Stock Split

NRXP: NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering

BBW: Build-A-Bear Workshop, Inc. Reports Double-Digit Increase in Both Total Revenues and Pre-Tax Income for Fiscal 2022 and Introduces Expectations for Continued Growth in Fiscal 2023

GRNA: GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day

ALNY: Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

ATAK: Aurora Technology Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Deadline to Consummate Business Combination

IDEX: Made in California: Ideanomics subsidiary US Hybrid and Global Environmental Products begin manufacturing 18 zero-emission street sweepers for Caltrans

ACHR: After Unveiling Its Production Aircraft, Midnight, Last November Archer Nears Completion of Its First Build

FWBI: First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

HSDT: Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

AZN: TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

TMDI: Titan Medical Announces Decision of Nasdaq Hearings Panel to Delist Common Shares

SNGX: Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

VITL: Vital Farms Sets Three ESG Goals and Celebrates Progress Towards Improving the Lives of People, Animals, and the Planet Through Food in 2023 Impact Report

SPRC: SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

To Your Success!

These earnings winners are red hot 🔥 (2024)

FAQs

What does "earnings beat" mean? ›

Research firms then compile these forecasts into the "consensus earnings estimate." When a company beats this estimate, it's called an earnings surprise, and the stock usually moves higher. If a company releases earnings below these estimates, it is said to disappoint, and the price typically moves lower.

Discover More Details ›

What company has the best earnings? ›

Companies ranked by earnings

#	Name	C.
1	Saudi Aramco 12222.SR	🇸🇦 Arabia
2	Apple 2AAPL	🇺🇸
3	Microsoft 3MSFT	🇺🇸
4	Berkshire Hathaway 4BRK-B	🇺🇸

57 more rows

Keep Reading ›

What is a good EPS? ›

There's no definition of a “good” or “bad” EPS value. But all other things being equal, the higher a company's EPS is, the better. The opposite is true for a company's price-to-earnings (P/E) ratio. In most cases, the lower a company's P/E ratio is, the better.

Read On ›

What are EPS shares? ›

Earnings per share (EPS) is a measure of a company's profitability, calculated by dividing quarterly or annual income (minus dividends) by the number of outstanding stock shares. The higher a company's EPS, the greater the profit and value perceived by investors.

Discover More Details ›

Why do stocks go down after earnings beat? ›

When a company releases an earnings report, a fundamental reaction is often the most common. As such, good earnings that miss expectations can result in a downgrade of value. If a firm issues an earnings report that does not meet Street expectations, the stock's price will usually drop.

How do you explain earnings? ›

Earnings refer to the income that an individual or organization gains during a certain period. EBITDA, EBIT, EBT, and net income can be calculated from the top to bottom of an income statement. Earnings can be used in relative valuation through the ratios such as P/E and EV/EBITDA.

Know More ›

Which company is best for earning? ›

#1 Apple Inc.
#2 Microsoft Corp.
#3 Alphabet Inc.
#4 Ind. and Comm. Bank of China.
#5 ExxonMobil Corp.
#6 JPMorgan.
#7 China Construction Bank.
#8 Agricultural Bank of China.

More items...

Know More ›

What company makes the most money in the US? ›

The most profitable company in the U.S. is Apple, with $94.68 billion in profit earned during their 2022 fiscal year, which began on Sept. 26, 2021, and ended on Sept. 24, 2022. Apple's profits during this time were 64.9% higher than the profits earned during the 2021 fiscal year.

Read On ›

What is the most profitable company on Earth? ›

1) Saudi Aramco – $247.43 Billion

In 2023, Saudi Aramco, the Saudi Arabian oil giant, raked in the highest net revenue globally, scoring profits of over 247 billion U.S. dollars.

Get More Info ›

What is considered bad EPS? ›

A company with positive annual EPS is considered profitable, while a company with negative annual EPS is considered unprofitable. As an example, let's look at one of the largest companies in the S&P 500 index.

View Details ›

Should I buy a stock with negative EPS? ›

Even if a company has a negative EPS, which means it's losing money, the stock may still be worth buying. In the case of Amazon, for example, the company had a negative EPS for a long period of time, but its stock price still increased because of other indicators, including its massive market share.

What is a good PE ratio? ›

As far as Nifty is concerned, it has traded in a PE range of 10 to 30 historically. Average PE of Nifty in the last 20 years was around 20.* So PEs below 20 may provide good investment opportunities; lower the PE below 20, more attractive the investment potential.

Is EPS risky? ›

Since EPS is so widely used by investors who choose stocks, a high EPS can attract investors and further drive up share prices. Low or decreasing earnings per share means that a company is less likely to distribute some of its profits to shareholders as dividends. As a result, such a company can be a risky investment.

What can EPS tell you? ›

Key Takeaways. Earnings per share (EPS) is a company's net income subtracted by preferred dividends and then divided by the number of common shares it has outstanding. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.

Explore More ›

What is a good dividend yield? ›

What Is a Good Dividend Yield? Yields from 2% to 6% are generally considered to be a good dividend yield, but there are plenty of factors to consider when deciding if a stock's yield makes it a good investment. Your own investment goals should also play a big role in deciding what a good dividend yield is for you.

Learn More Now ›

Is it better to buy before or after earnings? ›

If you believe a company will post strong earnings and expect the stock to rise after the announcement, you could purchase the stock beforehand. Conversely, if you believe a company will post disappointing earnings and expect the stock to decline after the announcement, you could short the stock.

Do stocks go up after earnings calls? ›

Earnings accouncements have an effect on the share price, which will move up or down depending on the company's performance. Analysts estimate how the company will perform, but these expectations can rapidly adjust up or down in the days leading up to the announcement.

Read The Full Story ›

How often do companies beat earnings? ›

It isn't all good news. About 75% of companies have beaten earnings forecasts, and the average beat has been by a whopping 8% according to Evercore. But just 60% of companies have beaten on sales, and the aggregate revenue result for the entire index has been less than 1% above analyst's estimates.

Keep Reading ›

Should you listen to earnings calls? ›

Investors should treat earnings calls as valuable information on a company but know that it doesn't typically paint the complete picture of its potential performance. Additionally, it may help to listen to the tone of the company's executives when they are talking about the company's performance.

Learn More Now ›